In brief: Benitec, XRT, Phylogica, Norwood Abbey
Wednesday, 06 April, 2005
RNAi specialist Benitec (ASX:BLT) has lodged a prospectus with ASIC to raise up to AUD$9.7 million in a rights issue, underwritten by Bell Potter. Capital raised will go towards clinical development and expansion of Benitec's California operations, it said.
Unlisted imaging company XRT, an investee of BioTech Capital (ASX:BTC), has entered a deal in which an unnamed analytical company will incorporate XRT's phase contrast technology in 3D metrology and analysis instruments.
Drug discovery firm Phylogica (ASX:PYC) has named former Peptech and CSL executive Dr Greg Pullen as its chief operating officer. Most recently, Pullen was in charge of licensing at Auckland University's commercialisation entity.
Norwood Abbey (ASX:NAL) has won TGA approval for a key component of its vision correction surgery tool Epi-Lasik.
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
Dopamine helps our brains to let go of memories
In a discovery that could reshape how we think about memory, researchers at Flinders University...
